Li Shu, Wang Zhan, Lin Liming, Wu Zhaoxing, Yu Qingfeng, Gao Feiqiong, Zhang Jiawei, Xu Yang
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
J Cancer. 2019 Jan 1;10(2):530-538. doi: 10.7150/jca.25732. eCollection 2019.
BCL6 (3q27) rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma (DLBCL). Previously, studies on the association between BCL6 rearrangement and DLBCL outcome remain controversial. Here we systematically reviewed literatures to identify the prognostic significance of BCL6 rearrangement in DLBCL. Meta-analytic methods are used to obtain pooled estimates of the association between BCL6 rearrangement and prognosis in DLBCL patients treated with different chemotherapy regimens. A total of 22 studies are enrolled in the cohort, involving 3037 patients. BCL6 rearrangement is verified to be negatively associated with overall survival (OS) (HR=1.36, p=0.000), but not with progression-free survival (PFS). Moreover, the subgroup analyses show that BCL6 rearrangement is prognostic only in DLBCLs treated with rituximab-containing regimens.
BCL6（3q27）重排是弥漫性大B细胞淋巴瘤（DLBCL）中最常见的染色体异常。此前，关于BCL6重排与DLBCL预后之间关联的研究仍存在争议。在此，我们系统地回顾了文献，以确定BCL6重排在DLBCL中的预后意义。采用荟萃分析方法来获得接受不同化疗方案治疗的DLBCL患者中BCL6重排与预后之间关联的合并估计值。该队列共纳入22项研究，涉及3037例患者。BCL6重排被证实与总生存期（OS）呈负相关（HR=1.36，p=0.000），但与无进展生存期（PFS）无关。此外，亚组分析表明，BCL6重排仅在接受含利妥昔单抗方案治疗的DLBCL中具有预后意义。
